Related Experiment Videos
Second line chemotherapy for NSCLC: establishing a gold standard
Frank V Fossella1, Thomas Lynch, Frances A Shepherd
1University of Texas, MD Anderson Cancer Center, 1515 Holcombe Blvd, Box 432, Houston, TX 77030, USA.
Lung Cancer (Amsterdam, Netherlands)
|December 14, 2002
Summary
Second-line docetaxel significantly improves survival and delays disease progression in non-small cell lung cancer (NSCLC) patients. This treatment offers a clinically meaningful benefit and is safe for patients with advanced NSCLC.
Area of Science:
- Oncology
- Medical Oncology
- Clinical Trials
Background:
- Non-small cell lung cancer (NSCLC) is a leading cause of cancer-related mortality.
- Effective second-line treatment options for advanced NSCLC remain a critical unmet need.
- Docetaxel has emerged as a potential therapeutic agent in this setting.
Purpose of the Study:
- To evaluate the efficacy and safety of docetaxel as a second-line treatment for non-small cell lung cancer (NSCLC).
- To compare docetaxel treatment with best supportive care and other chemotherapeutic agents.
- To assess the impact of docetaxel on survival rates, disease progression, and quality of life.
Main Methods:
- Two randomized clinical trials (TAX 317 and TAX 320) were conducted.
- Patients with advanced NSCLC received either docetaxel (75 mg/m(2) or 100 mg/m(2)) or a comparator treatment (best supportive care, vinorelbine, or ifosfamide).
- Outcomes assessed included 1-year survival rate, time to disease progression, and quality of life.
Main Results:
- Docetaxel (75 mg/m(2)) significantly improved the 1-year survival rate (37% vs. 12%) and prolonged time to disease progression (median 12.3 vs. 7.0 weeks) compared to best supportive care in study TAX 317.
- In study TAX 320, docetaxel (both doses) significantly increased the proportion of patients without disease progression at 26 weeks compared to the comparator arm.
- One-year survival was significantly greater with docetaxel 75 mg/m(2) (32%) versus the comparator arm (19%).
- Quality of life was superior with docetaxel, and the need for tumor-related therapy was reduced.
- Prior paclitaxel exposure did not diminish the benefits of docetaxel.
Conclusions:
- Second-line treatment with docetaxel (75 mg/m(2)) offers a safe and clinically meaningful benefit for patients with advanced non-small cell lung cancer (NSCLC).
- Docetaxel demonstrates superior efficacy in terms of survival and disease control compared to best supportive care and other agents.
- Future research may explore combinations of docetaxel with molecular-targeted agents, such as EGFR tyrosine kinase inhibitors.